Evidence map›Paper›PMID 38451429›Full record

ArticleDigestive diseases and sciences2024

Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study.

Jing Huang, Ge Gao, Yang Ge, Jianzhou Liu, Hongtu Cui, Ren Zheng, Jialin Wang, Si Wang, Vay Liang Go, Shen Hu and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Artificial intelligence in pancreatic cancer: applications in early detection, tumor staging, and survival prediction-a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Pancreatic cancer in 2025: Have we found a solution?World journal of gastroenterology · 2025
    Review
  5. Unraveling the therapeutic landscape of miRNAs in pancreatic cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jing HuangNational Key Laboratory of Fine Chemical Engineering and Department of Pharmacology, School of Chemical Engineering, Dalian University of Technology, Dalian, China.
Ge GaoDepartment of Laboratory Medicine, The Second & The Third Xiangya Hospitals, Central South University, Changsha, China.
Yang GeDepartment of Food Safety and Toxicology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianzhou LiuDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hongtu CuiSchool of Biomedical Engineering, Dalian University of Technology, Dalian, China.
Ren ZhengNational Key Laboratory of Fine Chemical Engineering and Department of Pharmacology, School of Chemical Engineering, Dalian University of Technology, Dalian, China.
Jialin WangNational Key Laboratory of Fine Chemical Engineering and Department of Pharmacology, School of Chemical Engineering, Dalian University of Technology, Dalian, China.
Si WangNational Key Laboratory of Fine Chemical Engineering and Department of Pharmacology, School of Chemical Engineering, Dalian University of Technology, Dalian, China.
Vay Liang GoThe UCLA Agi Hirshberg Center for Pancreatic Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Shen HuThe UCLA Agi Hirshberg Center for Pancreatic Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Yefu LiuDepartment of Hepatopancreatobiliary Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, China.
Minwei YangDepartment of Biliary-Pancreatic Surgery, School of Medicine, Ren Ji Hospital,, Shanghai Jiao Tong University, Shanghai, China.
Yongwei SunDepartment of Biliary-Pancreatic Surgery, School of Medicine, Ren Ji Hospital,, Shanghai Jiao Tong University, Shanghai, China.
Dong ShangClinical Laboratory of Integrative Medicine , Department of General Surgery, Pancreaticobiliary Center, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Yantao TianPancreatic and Gastric Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zhigang ZhangState Key Laboratory of Oncogenes and Related Genes, School of Medicine, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai, China.
Zhongyuan XiangDepartment of Laboratory Medicine, The Second & The Third Xiangya Hospitals, Central South University, Changsha, China.
Hongyang WangNational Center for Liver Cancer, Shanghai, China.
Junchao GuoDepartment of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gary Guishan XiaoNational Key Laboratory of Fine Chemical Engineering and Department of Pharmacology, School of Chemical Engineering, Dalian University of Technology, Dalian, China. gxiao@dlut.edu.cn.

Funding

Kante Seeds Foundation for Cancer Research KD2021030001Natural National Science Foundation of China 81642006Natural National Science Foundation of China 81770846US Hirshberg Foundation for Pancreatic Cancer Research AH201901083
6 · The paper itself

Abstract

backgroundA grim prognosis of pancreatic cancer (PCa) was attributed to the difficulty in early diagnosis of the disease.

aimsIdentifying novel biomarkers for early detection of PCa is thus urgent to improve the overall survival rates of patients.

methodsThe study was performed firstly by identification of candidate microRNAs (miRNAs) in formalin-fixed, paraffin-embedded tissues using microarray profiles, and followed by validation in a serum-based cohort study to assess clinical utility of the candidates. In the cohorts, a total of 1273 participants from four centers were retrospectively recruited as two cohorts including training and validation cohort. The collected serum specimens were analyzed by real-time polymerase chain reaction.

resultsWe identified 27 miRNAs expressed differentially in PCa tissues as compared to the benign. Of which, the top-four was selected as a panel whose diagnostic efficacy was fully assessed in the serum specimens. The panel exhibited superior to CA19-9, CA125, CEA and CA242 in discriminating patients with early stage PCa from healthy controls or non-PCa including chronic pancreatitis as well as pancreatic cystic neoplasms, with the area under the curves (AUC) of 0.971 (95% CI 0.956-0.987) and 0.924 (95% CI 0.899-0.949), respectively. Moreover, the panel eliminated interference from other digestive tumors with a specificity of 90.2%.

conclusionsA panel of four serum miRNAs was developed showing remarkably discriminative ability of early stage PCa from either healthy controls or other pancreatic diseases, suggesting it may be developed as a novel, noninvasive approach for early screening of PCa in clinic.

Indexed as

MicroRNAsPancreatic NeoplasmsBiomarkers, TumorCohort StudiesEarly Detection of CancerHumansRetrospective StudiesBiomarkers, TumorMicroRNAsCirculating microRNADiagnosisNoninvasive biomarkerPancreatic cancerSerum

Identifiers

PMID38451429
PMCPMC11026211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.